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ABSTRACT
Development of a Method to Study Thromboembolism by
Direct Observation in Blood-Contacting Microsystems
Using High-Definition Video Microscopy
Yong Min Kim
Department of Chemical Engineering
Masters of Science
A unique and novel method to study thromboembolism by direct observation was
developed. High-definition videos of thrombus formation and embolization were successfully
obtained in miniature flow cells using in-vitro, non-invasive, real-time techniques. Critical
parameters of thromboembolism such as thrombus growth rate, thrombus growth direction, shear
force on the thrombus at embolization, and adhesion strength of the thrombus to the foreign
surface were determined.
Thrombus growth was found predominantly in two locations: 1) in the flow recirculation
zone just after the trailing edge of the small tubes (53%) and 2) at the leading edge of the small
tubes (47%). In the small tubes, thrombus volume and shear force acting on the thrombus
increased in a power-law like function of time. In the large tubes, thrombus volume and shear
force acting on the thrombus increased in a linear like function of time. The slope of thrombus
growth rate in the small tubes was significantly greater than that in the large tubes. Thrombus
growth direction was also estimated by tracking the thrombus center of mass with respect to time
and typically ranged from 15 to 35 degrees from the direction of flow.
According to observations, embolization seems to occur via two possible mechanisms: 1)
complete detachment of the thrombus by sliding off the foreign surface or 2) partial embolization
of the thrombus by internal tearing. The estimated shear force on the thrombus at embolization
was determined and was significantly greater in the small tubes than in the large tubes. The
adhesion strengths of thrombi were calculated for the small tubes using the shear force at
embolization and the estimated thrombus attachment area and ranged from 9.63 to 28.83 N/m2
(mean = 16.24 ± 2.59 N/m2 95% confidence), which was in good agreement with published
results of platelet retention experiments.
An experimental series demonstrated that the developed method could be used to study
the effects of controlled variables on thromboembolism parameters. In that series, heparin
concentration in blood, blood flow rate, and device design were studied one variable at a time to
test their effects on thrombus growth parameters and adhesion strength. Because of the small
number of data, these preliminary results were statistically insignificant but pointed the way for
future studies.
Keywords: Yong Min Kim, thrombosis, thromboembolism, blood-contacting devices
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CHAPTER 1: INTRODUCTION

Blood-contacting devices are becoming increasingly more integral to the field of
medicine. They are used in applications such as cardiopulmonary bypass surgeries, hemodialysis,
vascular stents and shunts, and artificial hearts [1-3]. Even though significant progress has been
made in developing blood-contacting devices over the past 50 years, such devices are limited in
their effectiveness because of adverse blood-material interactions. The most common problem
that occurs in these devices is thromboembolism, which results when blood contacts a foreign
surface [4].
The phenomenon of thromboembolism can be divided into two parts: thrombosis
(thrombus formation) and embolism (thrombus detachment). Thrombosis is the accumulation of
blood platelets either within blood vessels or on the surfaces of biomaterials. Thrombus
formation naturally occurs within the body when a blood vessel is injured and is beneficial
because it creates a hemostatic plug and arrests bleeding. However, if thrombi are formed when
a patient’s blood comes into contact with a foreign surface in a blood-contacting device and
subsequently embolize downstream, they can cause a blockage of blood circulation to vital
organs, causing local ischemia, coronary occlusion, or stroke.
Thrombosis that occurs in blood-contacting devices begins with the adsorption and
successive accumulation of plasma proteins along the foreign surface, followed by platelets
adhering to the protein layer or existing thrombi [5]. As a thrombus grows, its adherence to the
1

foreign surface can be overcome by hemodynamic shear forces acting upon it. Detachment of
the thrombus from the surface is known as embolism. Free-floating segments of thrombi are
commonly referred to as thromboemboli, or simply emboli. The most common method of
preventing thromboembolism within blood-contacting devices is to use anticoagulants such as
heparin. Overuse of these blood additives, however, can cause hemorrhagic and/or other drugrelated disorders [6]. Additionally, they don’t completely inhibit platelets or eliminate
thromboembolism.
Thromboembolism is difficult to understand due to the many variables that add to the
complexity of the phenomena. Patient-specific factors such as blood composition, diet, and
medication can have a major impact on thromboembolism. Other factors such as surface
chemistry between the blood and various biomaterials, changes in hemodynamic conditions, and
complexity of device design increase the difficulty of studying thromboembolism. Many
contributing factors of thromboembolism have been investigated in previous decades; however,
the overall understanding of thromboembolism in blood-contacting devices is still very limited.
The research presented in this thesis is a continuation of previous research conducted by
Goodman, et al. [7]. Their study used video microscopy to observe thromboembolism in an invitro model that mimicked a blood-contacting device. They also developed a system to detect
and analyze emboli in real time using a light-scattering microemboli detector (LSMD) and
constant pressure filtration (CPF).
The overall goal of this research was to develop a method to study thromboembolism in
blood-contacting devices by direct observation, and then use the developed method to gain a
better understanding of the characteristics of thromboembolism by estimating critical parameters
such as growth rate, growth direction, shear force on the thrombus, and adhesion strength. An
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additional goal was to demonstrate that the developed method could be used to study the effects
of controlled variables such as heparin concentration, flow rate, and device design on these
critical parameters of thromboembolism.

3

CHAPTER 2: BACKGROUND

2.1 Thrombus Formation
Within the human body, the formation of a thrombus most commonly results from one of
two situations. First, a disruption in the normal state of homeostasis results in the activation and
collection of platelets within a blood vessel. This is usually the result of a disease that causes the
improper activation of platelets and coagulation pathways. Second, an injury can cause the
activation of clotting factors, which leads to thrombus formation. External to the human body,
when blood interacts with foreign surfaces in blood-contacting devices during medical
procedures, thrombus formation occurs frequently and is a leading cause of complications when
these devices are used.
2.1.1 Normal Physiological Conditions
Under normal physiological conditions, thrombus formation does not occur due to the
thrombosis-resistant characteristics of the endothelial inner-lining of blood vessels [8]. The nonthrombogenic characteristics of the endothelium are caused by several factors. First, both
endothelial cells and platelets are highly negatively charged, and they repel each other [9].
Second, endothelial cells synthesize prostacyclin I2 (PGI2), which inhibits platelet aggregation
[10]. Endothelial cells also release thrombomodulin and heparin sulfate which are cofactors that
inhibit thrombin activity [11-12]. Thrombomodulin increases the ability of thrombin to activate
protein C, which in turn inactivates factor Va and factor VIIIa and causes a decrease in thrombin
5

concentration [13]. Endothelial cells can also release tissue plasminogen activators, which in
the presence of fibrin, initiates fibrinolysis and inhibits thrombus formation [9]. A summary of
the thromboresistant properties of the endothelium is shown in Figure 1.

Figure 1: Thromboresistant properties of the endothelium.
2.1.2 Blood Flow Response to Injury
When an injury, inflammation, or endothelial dysfunction occurs in a blood vessel, a
three-step mechanism ensues in order to arrest bleeding. First is the vasoconstriction of a
damaged blood vessel in order to slow blood loss [14]. Second is the formation of a platelet plug.
This occurs when the endothelial wall is damaged and the blood is exposed to subendothelial
collagen at the damaged location. The collagen promotes platelet adhesion at the damaged site,
and the combination of this contact and other rheological factors causes platelets to become
activated [15]. Activated platelets release chemicals such as adenosine diphosphate (ADP) and
thromboxane A2, which then activate other platelets and lead to the aggregation of more platelets
to the damaged site [16-17]. This process is illustrated in Figure 2.

6

Figure 2: Formation of a platelet plug after an injury to the blood vessel.
The final step in the three-step mechanism is coagulation. There are over dozen clotting
factors that exist in the blood. These clotting factors are proteins that, under normal conditions,
are inactive. When an injury occurs to a blood vessel, these clotting factors are activated in a
cascading sequence, with one clotting factor activating a second, which then activates a third and
so on [14]. The clotting cascade is shown in Figure 3.
As illustrated in Figure 3, both intrinsic and extrinsic pathways can result in the
activation of factor X. Factor X activates the prothrombin activator which converts prothrombin
to thrombin. Thrombin then acts as an enzyme to turn fibrinogen to fibrin. Fibrin fibers form a
loose mesh network. Factor XIII stabilizes the fibrin to form dense fibrin polymers, and by
trapping erythrocytes and platelets a blood clot is formed [14]. This natural process of thrombus
formation in the body is very similar to the interactions of blood with foreign surfaces outside of
the human body. This phenomenon will be discussed in the next section.

7

Figure 3: Simplified illustration of coagulation cascade [4].
2.1.3 Blood Flow Response to Foreign Surfaces
When blood comes into contact with a foreign surface that is non-endothelial in nature,
the proteins in the blood first adsorb onto the artificial surface [18-20]. At the same time, blood
platelets are activated by coming into contact with the foreign surface and other rheological
factors. Activated platelets begin to adhere to the protein layer created by protein deposition.
Activated platelets also promote further platelet adhesion by releasing agents such as ADP,
thromboxane A2, and thrombin, which activate and attract more platelets to the site of the

8

thrombus formation and stimulate the coagulation cascade [21]. This process is illustrated in
Figure 4.

Figure 4: Mechanism of thromboembolism in blood-contacting devices.
2.2 Embolization
As the thrombus grows, the shear force on the thrombus increases due to the reduction of
the cross-sectional flow area. When these hemodynamic shear forces become greater than the
adhesion strength of the thrombus to the foreign surface, the thrombus detaches from the surface.
This process creates a free-floating particle in the blood, often referred to as an embolus or
thromboembolus. Depending on the size and cohesive strength of the embolus, it may become
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broken up into harmless smaller parts, reattach to another surface or thrombus, or lodge in
smaller vessels downstream, which can result in serious complications due to vessel blockages.
2.3 Fluid Dynamics of Thromboembolism
While there are many factors that contribute to thromboembolism, the dynamics of blood
flow within a blood-contacting device is believed to be one of the most important factors. Fluid
dynamics of blood flow facilitate the transport of platelets and other reacting agents to the
surface of biomaterials and existing thrombi by mass-transfer methods of diffusion and
convection. In addition, platelets and other reacting agents are known to be activated by shear
stresses within the blood flow [22]. Last, the most important factor of embolization of thrombi is
considered to be the shear force on the thrombus.
2.3.1 Diffusion
Diffusion is one of the primary methods of transfer for platelets and other blood
components to a foreign surface and to an existing thrombus. Diffusion of platelets and other
blood components may be increased by the presence and rotation of erythrocytes (red blood cells)
caused by shearing blood flow [23-24]. An increase in apparent platelet diffusivity enhances the
rate of platelet adhesion to foreign surfaces and to existing thrombi, thus increasing the rate of
thrombus growth.
2.3.2 Convection
Under normal conditions in the body, the convection of blood components toward a
surface is minimal as most blood flow in the body is laminar. The exception is at locations
where vessels branch or constrict. Similarly, in blood-contacting devices, the convective
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transport of platelets and other blood components toward the surface of a biomaterial is induced
by curvature and/or abrupt changes in the cross-section of a flow [25].
At these locations, convective forces within the blood flow introduce secondary flow
effects that transport platelets and other reacting agents closer to the foreign surface and existing
thrombi. In cases where there is a dramatic disruption of the flow stream, flow separation occurs
and causes the momentum of the main stream to rotate, creating flow recirculation zones. An
illustration of this phenomenon is shown in Figure 5. Blood in the recirculation zones
experiences increased residence time, which allows longer exposure of thrombogenic agents to
foreign surfaces and existing thrombi [26].

Figure 5: Recirculation zones created due to flow separation.
As a thrombus develops, it may cause local flow disturbances that further increase the
convective transport of platelets and other blood components to the existing thrombi or to the
foreign surface, leading to an increase in thrombus growth. Also, an existing thrombus may
create a recirculation zone on the back side of the thrombus, leading to an increase in thrombus
growth [27]. This is illustrated in Figure 6.
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Figure 6: Flow disturbances caused by an existing thrombus.
2.3.3 Shear Stress
Shear stress within blood flow is often considered to be one of the most important fluid
dynamic factors that affect thromboembolism. Shear stress causes red blood cells to rotate,
which increases the apparent diffusivity of platelets and other blood components to the surface of
the biomaterials or the existing thrombi [28]. Shear stress is also considered as one of the main
causes that activates platelets through deformation [29-30]. Even at shear stress less than 10 Pa,
platelets release components such as ADP, thromboxane A2, and thrombin, which leads to
increased platelet surface adhesion and aggregation [31-32].
Shear stress is also a major factor for embolization. As the thrombus grows, it
experiences an increase in shear force due to the increased surface area that is exposed to the
blood flow. If the shear force on the thrombus exceeds the adhesion force between the thrombus
and the biomaterial surface, embolization will occur.
The shear force on the thrombus can be quantified using the following equation:
F=τ·A
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(1)

where F represents the shear force on the thrombus, A is the surface area of the thrombus
adjacent to the flow, and τ is the shear stress acting on the thrombus. The shear force can be
estimated by applying Eq. 1 to differential slices of the thrombus and summing the resulting
pieces, as expressed in Eq. 2.
F = ∑ (τ · As)

(2)

where As represents the surface area of a slice of the thrombus.
For Newtonian fluids, shear stress, τ, can be described by the following equation:
τ=µ

ν

(3)

Assuming a one-dimensional flow of Newtonian fluid, shear stress can be described by the linear
relationship:
τ = -µ ·
where µ represents the viscosity of the blood and

(4)
represents the rate of change of fluid

velocity with respect to the perpendicular distance from the thrombus surface.
2.4 Pharmacological Agents
Due to the damaging consequences of an embolus lodging in a blood vessel and blocking
blood flow, the use of pharmacological agents to minimize thrombus formation is often used in
clinical environments. These pharmacological agents are either anticoagulants or antiplatelet
agents (i.e. platelet inhibitors).
Heparin has become the most commonly used anticoagulant in both clinical and research
settings [33]. Heparin works by binding and activating antithrombin III. Active antithrombin III
then inactivates thrombin and other factors that contribute to coagulation, including factors Xa,
XIa, and IXa. Antithrombin III then forms a 1:1 irreversible complex with the coagulation
13

enzymes, and the heparin dissociates from the complex. Dissociated heparin can be reused to
bind and activate antithrombin III. The anticoagulant activity of heparin is useful in situations
where clot formation must be prevented; however, it will not actively break up already existing
thrombus clots [33-34].
Warfarin is also a common anticoagulant used following the implantation of
cardiovascular devices, such as vascular grafts and artificial valves. Warfarin works by
interfering with the blood’s vitamin K cycle by reducing the production of vitamin K-dependent
coagulation proteins such as prothrombin, Factor VII, Factor IX, and Factor X [35].
Another commonly used pharmacological agent is aspirin, which is a platelet inhibitor.
Aspirin is used for therapeutic purposes after various cardiovascular surgeries in order to prevent
potential thromboembolism-related issues such as heart attack and stroke. Clopidogrel (better
known as Plavix) is also used for a similar purpose. This agent works by blocking ADP
aggregation, whereas aspirin inhibits platelet activation by irreversibly inactivating platelet
cyclooxygenase [36].
Due to undesirable complications such as hemorrhaging, the use of anticoagulants and/or
antiplatelet agents in clinical situations must be well-controlled. Optimal levels of these agents
are unique for each individual in each situation, and understanding their effects on thrombus
growth and embolization requires further research.
2.5 Previous Research on In Vitro Model Microsystems
As part of an ongoing research at Brigham Young University, a low-volume in vitro
model that observes thrombus growth and embolization has been developed and improved over
the past 15 years [7]. In this model, fresh human blood is passed through a miniature flow cell
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that mimics a blood-contacting device, and thromboembolism is visualized and detected
continuously through non-invasive techniques.
The flow cell was originally built by inserting four 1 mm segments of Teflon tubing into
1/32 inch I.D. PVC tubing with 1 mm of space between each segment. The flow rate of the
blood through the flow cell was set at 3 mL/min using a syringe pump, while the temperature of
the blood was held constant at 37oC. This model was designed to produce repeatable flow
disturbances that caused a high level of rotational flow, thus increasing the transport of platelets
and other blood components to the wall and the shear stress within the flow.
Thromboembolism was then observed and recorded in real-time using video microscopy,
as shown in Figure 7. Emboli were continuously detected using a light-scattering microemboli
detector (LSMD) [37]. The LSMD monitors embolization by differentiating the light-scattering
patterns created by emboli within the flow. As thrombi embolize and travel downstream through
the transparent tube, laser light is directed into the tube, and the light scatters from the emboli.
The change in magnitude of the light-scattering intensity is dependent on the size of the emboli.
The LSMD captures the thromboembolism activity level by gathering the number and the size of
the emboli.

Figure 7: Goodman experimental model [7].
15

The relative strength of the emboli was determined by using a method of constant
pressure filtration (CPF) [7]. About 1 mL of blood was collected from the end of the flow cell.
This blood sample was then passed through a filter with 20 µm pores at a pressure 50 mm Hg.
The relative strength of the emboli was determined by the amount of blood passed through the
filter. If the emboli were large (larger than 20 µm) and/or strong, the blood did not pass through
the filter due to clogging; however, if the emboli were weak and/or small (less than 20 µm), they
passed through the filter or broke apart due to the applied pressure gradient.
The study results showed that thrombus growth was observed in areas with high
rotational flow, such as at sharp corners and/or reattachment and separation zones [7]. This
study demonstrated the potential of using a low volume in-vitro model to investigate the
relationship between the nature of blood flow and the progression of thromboembolism in bloodcontacting devices. It did not show, however, how certain change in flow properties or device
design affected the thromboembolism characteristics.
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CHAPTER 3: OBJECTIVES

The overall goal of this research was to develop a method to study thromboembolism in
blood-contacting devices by direct observation using in-vitro, non-invasive, real-time techniques.
The second goal was to use this method to gain a better understanding of the characteristics of
thrombus formation, growth and embolization by estimating critical parameters such as growth
rate, growth direction, shear force on the thrombus, and adhesion strength. The last goal of this
research was to demonstrate that the developed method can be used to study the effects of
controlled variables such as heparin concentration in blood, blood flow rate, and device design
on these critical parameters. To accomplish these goals, the specific objectives of this study
were set as follows:
1) Acquire high-definition video recordings of blood thrombus formation and embolization
in miniature flow cells under various conditions from which characteristics of
thromboembolism can be quantified.
2) Use image analysis software and the acquired videos to quantify critical parameters of
thromboembolism: the thrombus growth rate, the thrombus growth direction (angle of
growth vector at center of mass of thrombus relative to flow channel lumen), the shear
force on the thrombus, and the adhesion strength of thrombus to the foreign surface.
3) Correlate these critical parameters of thromboembolism with changes in controlled
variables: blood flow rate, heparin concentration level in blood, and device design.

17

CHAPTER 4: DEVELOPMENT OF EXPERIMENTAL MODEL

As noted in Section 2.5, the experimental set-up in this research was an extension of a
previously developed model presented by Goodman et al. [7]. An overview of the experimental
set-up can be seen in Figure 8. The experimental set-up was comprised of the following
components: flow cell, syringe pump, high-definition video microscope, and light-scattering
microemboli detector LSMD. These components are each described in detail in the following
sections.

Figure 8: Illustration of experimental set-up.
4.1 Development of Flow Cell
Many flow cells that mimic blood-contacting devices have been developed in the past to
study thromboembolism [38]. However, most flow cells developed previously did not create
significant disturbances within the flow, which are necessary to increase the transport of platelets
19

and other blood components to the wall of the foreign surface. Therefore, an important aspect of
this research was developing a flow cell that caused enough flow disturbances to help mimic the
thromboembolism observed in real blood-contacting devices.
In this study, a cylindrical, translucent micro flow cell that mimics a blood-contacting
device was prepared using a Miro-Renathane polyurethane tube from Braintree Scientific®
(Braintree, MA). A 21-inch section of tubing (0.04” O.D. and 0.025” I.D.) was cut using a razor
blade. Segments of tubing (0.025” O.D. and 0.012” I.D.) that were 1-mm in length were inserted
into the larger-diameter tube, 8 inches from one end using a metal wire and warm water. The
two small tubes were separated from each other by either 1 mm or 0.5 mm depending on the
desired experimental condition. The small tube inserts created repeatable flow disturbances and
thus increased the transport of platelets and other blood components to the surface of the
biomaterial.

Figure 9: Small tube inserts in the flow cell A) illustration B) actual.
After insertion of the two small tubes, one end of the flow cell (not the end through which
the steps were inserted) was threaded through a Luer connector and out the other side. In this
way, the tubing actually protruded into the syringe, thus the blood contacted only the tubing
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during the experiment. The Luer fitting was anchored and sealed with Parafilm® as shown in
Figure 10.

Figure 10: Luer fitting attachment of the flow cell.
Before use, each flow cell was rinsed with a 5% ethanol-water solution, then rinsed with
distilled water and allowed to dry to ensure no bacteria or other particles remained on the inside
of the flow cell. After the flow cells were dry, the tips of tubing protruding from the Luer
connectors were coated with a 100 unit/mL heparin/benzalkonium chloride solution and dried for
a minimum of 24 hours. This preparation method of the flow cell helped to prevent any clotting
from occurring at the connection between the syringe and the flow cell entrance region.
4.2 Syringe Pump Set-up
During the experiment, it was necessary to keep the blood at a constant temperature of
37o C to avoid hypothermia. Therefore, the syringe pump was placed in a clear Plexiglas box
with a heating coil and a fan to keep the blood in the syringe at 37o C. It was also important to
keep the blood well-mixed throughout the experiment to prevent the separation of plasma and
red blood cells in the blood sample. To accomplish this goal, the syringe pump was attached to
an apparatus which allowed the pump to be flipped 180o every three minutes during the
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experiment. If a certain donor’s blood was known to separate more quickly than normal, the
syringe pump was flipped every two minutes to minimize the settling or separation of the blood
components.
The flow rate of the blood in the flow cell was controlled by the syringe pump with
settings that could be changed to desired specifications. The desired settings allowed the syringe
pump to push the blood sample into the flow cell at a constant flow rate. A detailed set-up of the
syringe pump system used for the experiment is shown in Figure 11.

Figure 11: A) Syringe pump set-up B) Syringe pump rotation.
4.3 High-Definition Video Microscopy
A high-definition camera (Cannon EOS Rebel T1i) and microscope (Bausch & Lomb,
Stereozoom 7) were used to make high-definition videos of thromboembolism occurring within
the flow cell. First, the area of the flow cell containing the two small steps was secured under
the microscope by placing the flow cell into a metal ring with a slit on each side. The metal ring
was placed in a translucent plastic dish that was held above the base of the microscope by metal
wires configured in the shape of the dish. This allowed the light to penetrate through the blood
at all angles as it passed through the flow cell.
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Two gooseneck fiber optic lights (AO Scientific Instruments) were used to illuminate the
steps in the flow cell under the microscope. The optimum brightness was used to allow
maximum transparency of the blood while minimizing any glare from the tubing. It is important
to note that the flow cell was submerged in mineral oil, which has a refractive index (1.4761.483) similar to that of polyurethane tubing (approximately 1.5) and enhanced the transparency
of the blood flow.

Figure 12: A) Set up of high-definition video microscopy B) Secured
flow cell under the microscope.
The submerged flow cell was positioned under the viewing field of the microscope to
capture the growth of a thrombus in the projected area with a high-definition camera. The
recordings of the thrombus growth were viewed during the experiment on an HDMI Screen that
was connected to the high-definition camera.
4.4 Light Scattering Microemboli Detector (LSMD)
As shown in Figure 8, the outlet section of the flow cell was placed into a laser cuvette.
About one inch of tubing extended past this cuvette to allow the blood to drip from the end of the
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tube into a plastic dish, which allowed for easy disposal of the blood at the end of the experiment.
The laser cuvette contained one laser diode that shined straight down onto the flow cell and two
detectors that determined the scattering of the laser light. Prior to all experimental runs, a base
level of light scattering for unaltered blood was determined.
The light-scattering microemboli detector (LSMD) monitors embolization by
differentiating the light-scattering patterns created by flowing emboli from red blood cells and
other blood components within the flow cell [37]. As thrombi embolize and travel downstream
through the flow cell, they pass through the laser light illuminating the tube. A detected change
in magnitude of the scattered light intensity is dependent on the size of the emboli.
Accumulation of size and number of the emboli in the flowing tube determines the
thromboembolic activity level.
After the base level was determined, a LabView®(National Instruments) program was
used to measure the amount of scatter relative to this level, giving an effective emboli count.
When the syringe pump was flipped (as discussed in Section 4.2) the counting was turned off
momentarily due to the fact that the action of flipping may cause some settled particles within
the syringe to be released into the flow cell.
4.5 Blood Sample Preparation
Before blood was drawn from a donor, a syringe was prepared with the correct amount of
heparin drawn from a stock 100 units/mL solution. The fluid concentration was usually
specified to be 0.5 units/mL. Once the heparin solution was in the syringe, a 9-gauge needle
with tubing was attached to the syringe for drawing blood from the donor.
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Figure 13: A) Laser Cuvette B) LabView® C) LSMD Controller.
After the draw, the blood in the syringe was mixed for a few minutes by pulling some air
into the syringe and repeatedly rotating it 180o in order to mix the heparin solution with the
drawn blood. Then the air was pushed out, and the syringe was attached to the Luer head of the
flow cell and placed on the syringe pump, ready for the experiment.
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CHAPTER 5: EXPERIMENTAL DESIGN

5.1 Sample Selection
For this study, blood samples from a population of 33 donors (students from Brigham
Young University) were initially tested for visibility of thrombus growth under the microscope.
The variability of red cell content, platelet level, and other factors for each donor determine the
reactivity and visibility of thrombus growth and embolization under the microscope. Therefore,
an initial screening was conducted to identify donors that resulted in a high visibility of
thromboembolism in the flow cell.
For the initial screening process, 33 volunteers who had not taken any medications for at
least 2 weeks were brought in to test their blood response to the designed experiment. From each
donor, 30 mL of blood were drawn, and the blood was pushed through the flow cell using the
syringe pump under the following conditions: 1.0 mL/min flow rate, 0.5 units/mL heparin
concentration, and 1.0 mm of space between two small tubes. At the end of the population
screening, the blood samples from 8 donors were identified to have good visibility of thrombus
growth under the microscope.
Each of the 8 donors was brought back on a weekly basis to complete a set of
experiments to demonstrate that the developed method of studying thromboembolism can be
used to evaluate the effects of controlled variables such as heparin concentration, flow rate, and
the device design. The set of experiments is presented in Table 1.
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Table 1: Experimental conditions
Heparin concentration in blood

Blood Flow Rates

Spacing Between Two Small Tubes

Experiment 1

0.5 units/mL

1.0 mL/min

1.0 mm

Experiment 2

0.75 units/mL

1.0 mL/min

1.0 mm

Experiment 3

0.5 units/mL

0.5 mL/min

1.0 mm

Experiment 4

0.5 units/mL

1.0 mL/min

0.5 mm

The number of experiments required to develop the methodology combined with full factorial
design resulted in a prohibitive-large number of experiments. Therefore, this simplified design
was adopted where variables were tested one at a time against the baseline values. While this
simplified design ignores variable-variable interactions, it still provides value in demonstrating
that the developed method can be used to study the effects of controlled variables on
thromboembolism.
5.2 The Effect of Heparin Concentration in Blood
Two sets of experiments were conducted at different levels of heparin concentration
holding all other conditions the same. In Experiment 1, the heparin concentration level was set
at 0.5 units of heparin per mL of blood, and in Experiment 2, the concentration was changed to
0.75 units of heparin per mL of blood. Higher concentrations of heparin (above 0.75 unit/mL of
blood) yielded little to no visible thromboembolism under the microscope, while lower
concentrations (below 0.5 unit/mL of blood) often resulted in a prohibitive amount of clotting in
the apparatus.
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5.3 The Effect of Blood Flow Rate
Two sets of experiments were conducted at different flow rates holding all other
conditions the same. In Experiment 1, the flow rate of blood entering the flow cell was set at 1.0
mL/min (Re = 11.3), and in Experiment 3, the flow rate of blood entering the flow cell was
lowered to 0.5 mL/min (Re = 5.65). Lower flow rates (lower than 0.5 mL/min) often did not
result in visible thrombus growth under the microscope, and higher flow rates (greater than 1.0
mL/min) resulted in rapid embolization of thrombi, making it difficult to study
thromboembolism in real-time.
The CFD results from Star-CD® (CD-adapco) showed that there is a significant
difference in the velocity profiles for the two flow rates studied in this work. These CFD results
are shown in Figure 14.
B)

A)

Figure 14: Velocity vector profile of A) 1.0 mL/min B) 0.5 mL/min.
5.4 The Effect of Device Design Change
The design of blood-contacting devices is one of the most important factors that controls
thromboembolism in clinical settings, and is also one of the easiest variables to change to
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minimize thromboembolism. To demonstrate that the developed method can be used to study
the effects of device design change, two sets of experiments were conducted at different
distances between two small tubes holding all other conditions the same. In Experiment 1, the
distance between the two small tubes was 1.0 mm, and in Experiment 4, the distance between the
two small tubes was 0.5 mm. The separation distances were determined after the CFD results
from Star-CD® (CD-adapco) showed that the 1.0 mm distance between two inserts yielded flow
reattachment at the wall prior to the second small tube, whereas the 0.5-mm distance between the
small tubes yielded no reattachment of blood flow. These CFD results from Star-CD® (CDadapco) are shown in Figure 15.

A)

B)

Figure 15: Velocity vector profile of A) 1.0 mm separation between two small tubes and
B) 0.5 mm separation between two small tubes.
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CHAPTER 6: CALCULATIONS OF THROMBOEMBOLISM PARAMETERS

After the high-definition videos of thromboembolism were acquired, the image-analysis
software ImageJ (National Institutes of Health) was used to analyze the video for quantification
of key thromboembolism parameters. Parameters of interest for this research included thrombus
growth rate, thrombus growth direction, shear force on the thrombus, and adhesion strength of
thrombus to the foreign surface.
An illustration of a thrombus in a flow cell, similar to the images captured using video
microscopy for the current work, is shown in Figure 16.

Figure 16: Illustration of thrombus growth in the flow cell.

Since the image captured in the video is two-dimensional, the cross sectional shape of the
thrombus must be assumed. One logical assumption for the cross-sectional shape of the
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thrombus is that it can be determined by the overlap of two circles with cross sections equal to
that of the flow cell. The assumption of the cross-sectional shape of the thrombus used in the
current work is represented in Figure 17. The height of the overlap is determined by the height
of the thrombus as captured in the video microscopy images.

Figure 17: Assumed cross-sectional shape of the thrombus.
6.1 Calculation of Thrombus Growth Rate
In order to calculate the thrombus growth rate, the volume of the thrombus was estimated
frame-by-frame from the two-dimensional image of the video microscopy. With the proposed
assumption of the cross-sectional thrombus shape, the volume of the thrombus can be calculated
using the following equation.
V

A

=

∙ dx

As shown in Figure 18, the cross-sectional area of the thrombus can be determined by
first calculating the half-height cross-sectional area (cross-hatched) and then multiplying that
value by 2 (A

2∙A

.
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(5)

Figure 18: Terminology used in determination of thrombus area.
Using the terminology specified in Figure 18, the cross-sectional area of the thrombus was
derived as shown.
2∙

(6)
(7)

∙

(8)

cos

(9)
(10)

sin

Because A

A

(11)

A

A

, A
∙

∙

was defined as:
∙

∙

∙

(12)

Using Eq. 8, Eq. 12 was further simplified to:
A

∙ ∙
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∙

∙

(13)

Using the relationships shown in Eq. 8, 9, and 10, Eq. 14 was derived for the cross-hatched
section of the picture in Figure 18:
A

∙

∙√

)

(14)

Using Eq. 6 and 7, Eq. 14 was expressed in terms of height, H at any axial position, x:
A

∙

A

∙

is then 2 ∙ A

A

2∙

∙

(15)

, and

∙

∙

∙

(16)

After integrating across the length of the thrombus, the approximate volume of the thrombus at
any given time was calculated using Equation 17:
V

=

2∙

∙

∙

∙

∙ dx

(17)

Thrombus growth rate was estimated by using Equation 17 at each time frame of the experiment.
6.2 Calculation of Thrombus Growth Direction
The thrombus growth direction relative to the flow channel lumen was obtained by
comparing the changes in the location of the thrombus center of mass at each time frame. The
center of mass of the thrombus was determined from images taken from video microscopy using
image software Image J (National Institutes of Health). By plotting the position of the center of
mass at successive times, the direction of the growth was determined.
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6.3 Calculation of Shear Force on the Thrombus
As presented in Equation 2, shear force on the thrombus can be represented by
F = ∑ (τ · As)

(18)

where As represents the surface area of the thrombus wetted by the flow of blood. Assuming the
blood flow can be described by a one-dimensional Newtonian fluid, τ can be represented by
Equation 19.
(19)

τ = -µ ·
where µ represents the viscosity of the blood and

represents the rate of change of fluid

velocity with respect to the perpendicular distance from the thrombus surface. The shape of the
blood flow cross section will change significantly as the thrombus grows, moving from a circle
to a crescent as time passes. Therefore, the shear stress solution will need to adjust accordingly at
various stages of thrombus growth, as shown in Figure 19.

Figure 19: Illustration of thrombus growth stages.
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6.3.1 Shear Stress Calculation at Initial Stages of Thrombus Growth
At the initial stages of thrombus growth,

≪ 1, blood flow is similar to fully-developed

laminar flow through a cylindrical pipe. The velocity profile of this solution can be
approximated by Equation 20.
1

(20)

where is the radial position within the pipe. The velocity profile changes in the radial direction
according to Equation 21.
(21)
For fully-developed laminar flow through a cylindrical pipe,

2

shear stress across the surface of the thrombus at the initial stage,

≪ 1, can be approximated

. Therefore, the

by Equation 22.
τ

μ

(22)

6.3.2 Shear Stress Calculation at Advanced Stages of Thrombus Growth
At the advanced stage of thrombus growth, which can be defined by

1, shear stress

on the thrombus can be approximated by applying boundary-layer theory for flow between two
flat plates. This is because the flow over the large thrombus creates a constantly-changing
entrance region resulting in thin boundary layers at the surface but relatively-uniform velocity
outside of the boundary layers (Figure 20).
The shear stress on the wetted surface of the thrombus can be estimated by the von
Karman momentum balance [39] as shown in Equation 23.
μ

(23)
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For this system,

. Assuming flow near the surface over the thrombus can be

approximated by a flat-plate solution, the boundary-layer region can be sufficiently described by
the velocity profile in Equation 24.
(24)

where

represents the boundary layer thickness shown in Figure 20. This profile has been

defined such that

0 at

0 and

velocities outside the boundary layers,

at

. Because of the relatively-uniform

can be reasonably estimated to equal

.

Figure 20: Representation of , L, y, x during thrombus growth in flow cell.

Substituting Equation 24 into the von Karman momentum balance and solving the
differential equation results in Equation 25, which is a representation of the boundary-layer
thickness of blood flow through a passage partially obstructed by the growing thrombus.
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δ x
where

4.64

(25)

is the kinematic viscosity and x is the distance from the leading edge of thrombus.

Using Equations 24 and 25, we can calculate shear stress across the surface of the thrombus.
This is given in Equation 26.
τ
At the surface of the thrombus,

μ

1

(26)

0, therefore Equation 26 reduces to:
τ

(27)

6.3.3 Shear Stress Calculation for Intermediate Stages of Thrombus Growth
As the thrombus grows from the initial stages,

≪ 1 to the advanced stages,

1, the

solution for shear stress was described by a combination of the solutions for the initial and the
advanced stages as shown in Equation 28.
τ

(28)

where H(x) represents the thrombus height. Since advanced stage is defined by
initial stage is defined by

1 and the

close to 0, shear stress for an intermediate stage of thrombus growth,

1, was calculated using the ratio of height to radius.

6.3.4 Average Velocity Calculation
The average velocity,

, was calculated using the volumetric flow rate of the blood

and the cross-sectional flow area of the flow cell. Using Equation 6, the cross-sectional area of
the blood flow was defined as:
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A

2∙

∙

∙

∙

Using Eq. 29 and the known volumetric flow rate, an approximate

∙

(29)

for a given thrombus

height was expressed as.
(30)
∙

∙

∙

∙

∙

6.3.5 Calculation of Shear Force Acting on the Thrombus
The shear force on the surface of the thrombus (Equation 20) was calculated using the
integral form shown in Eq. 31, where P is represented in Figure 21.
F=

τ x ∙ P x dx

(31)

In Figure 19, P(x) represents the top perimeter of the thrombus cross-section at any point x. P(x)
was calculated by Equation 32.
P(x) = 2 ∙

∙

1

Figure 21: Illustration of the thrombus perimeter.
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(32)

Combining Eq. 31 and 32, the shear force on the thrombus at any given time was estimated using
Equation 33.
F= 2

τ x ∙

∙

1

dx

(33)

H(x) was obtained by fitting the shape of the thrombus at a given time, and the integral in
Equation 33 was then solved using numerical methods to determine the total shear force on the
surface of the thrombus.
6.4 Calculation of Adhesion Strength of Thrombus
The thrombus embolizes when shear force on the thrombus exceeds the adhesion strength
of the thrombus to the biomaterial. The adhesion strength was estimated by calculating the shear
force at which the thrombus embolized and dividing it by the thrombus-biomaterial attachment
area. The thrombus-biomaterial attachment area was calculated as shown in Equation 34.
Asurface-bottom =

P x dx

(34)

Thus, adhesion strength of thrombus was calculated as shown in Equation 35.
Sthrombus-adhesion =
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(35)

CHAPTER 7: RESULTS AND DISCUSSION

Using the experimental design presented in Chapter 5, high-definition videos of thrombus
formation and embolization in a miniature flow cell that mimics blood-contacting devices were
acquired. The high-definition video was recorded at 29 frames-per-second, which gave the video
a time resolution of 34.5 milliseconds. Therefore, any thromboembolism phenomena that
occurred at time scales longer than 34.5 milliseconds were captured. This time resolution was
deemed sufficient after viewing the first few acquired videos and noting that the pertinent
phenomena of thrombus growth were being captured. An example of the still frames taken from
the captured videos of thromboembolism is shown in Figure 22.

Figure 22: An example of a still frame taken from the captured video of thrombus growth
in the flow cell.
The actual process of embolization was also captured in some of the videos. However, capturing
embolization proved to be more difficult than anticipated due to how quickly the embolization
occurred. This will be discussed further in Section 7.2.
All data collected as part of this research and reported in this chapter will be presented as
means with 95% confidence intervals. The significance of differences were evaluated with
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Pearson’s chi-squared test and Student’s t-test. The results from the two statistical tests were in
agreement. In this work, statistical significance is presented with p-values from the Student’s ttest.
7.1 Thrombus Formation
The experimental techniques used for this research were well-suited to studying thrombus
formation and growth. Initial thrombus formation and steady thrombus growth were visible
under the microscope for long periods of time. Using the high-definition videos acquired, the
location of thrombus growth, thrombus growth rate, thrombus growth direction, and shear force
on the surface of the thrombus were each evaluated. Additionally, the effects of flow rate,
heparin concentration in blood, and small-tube spacing on these thrombus growth parameters
were explored. The 37 high-definition videos acquired showed a total of 129 growing thrombi,
of which 45 were analyzed and presented in this chapter.
7.1.1 Thrombus Growth Location
All 129 thrombi observed in this study grew in one of two locations within the flow cell.
These two locations are shown in Figure 23.

Figure 23: Common locations of thrombus growth within the flow cell
the small tube entrance and B) at the large tube following the small
tube exit.
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The location of thrombus growth shown in Figure 23A was at the entrance of a small tube.
Out of the 129 thrombi seen through the microscope, 61 (47%) were seen at this location. The
remainder of the visible thrombi, 68 (53%), grew in the large tubes immediately following the
small tube exit, as shown in Figure 23B.
The location of common thrombus growth within the large tubes can be explained by the
presence of a recirculation zone at that location. Blood in recirculation zones experiences an
increased residence time, which allows for longer exposure of flowing platelets and
thrombogenic agents in the blood to foreign surfaces and to existing thrombi [27].
Thrombus growth at the leading edge of the small tube is more difficult to explain.
Initially, it was believed that the constricted flow and sharp edge at the entrance of the small tube
caused the activation of platelets, and thus thrombi began to grow at that location. However,
further visual analysis showed that the thrombi may begin to grow within the recirculation zone
in the large tube just prior to the small tube entrance, and then spread up into the restricted flow
area in the small tube as they grow.
In most of the acquired videos, this phenomenon was difficult to observe due to the
limited transparency of blood in the large tubes. In a few cases, this phenomenon was captured,
and an example is shown in Figure 24.

Figure 24: Thrombus growth from large tube into small A) t = 0 B) t = 1:30 C) t = 2:42.
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In a perfect flow cell with cylindrical symmetry, the thrombus might be expected to form
uniformly around the inside of the tube at each axial location. However, experimental
observations show that thrombi form at random angular positions around the insides of the small
and the large tubes. This non-uniformity is probably due to inconsistencies and imperfections of
the flow cells. Although significant effort was put into making a well-built flow cell, the cut
faces of the inserts and the fit of the inserts against the tubing wall were seen to be irregular
when viewed under the microscope, which may have caused the variations of thrombus angular
growth location that were observed.
7.1.2 Thrombus Growth Rate
As discussed previously, steady thrombus growth was visible under the microscope in
real-time. An example of thrombus growth obtained is shown in Figure 25.

Figure 25: High-definition images of thrombus growth.
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From the 129 thrombi observed, 45 thrombi were analyzed. The high-definition video
was first imported into Image J (National Institutes of Health), which took individual still frames
from the video at specified time intervals. These images were analyzed by Image J, which
returned height vs. axial position data for the outer boundary of a visible thrombus. An example
of the Image J output is shown in Appendix A. For most video analyses, 30 second intervals
were used. An example of the conversion from video image to plotted boundary is shown in
Figure 26.

Figure 26: Comparison of A) video image to B) plotted boundary from Image J output.
An equation was fit to the graphical boundary data (Figure 26B), which represented the
height of the thrombus at any axial position at a given point in time. This equation was applied
to the calculation presented in Section 6 to determine the volume of the thrombus at that time.
An example of this calculation is shown in Appendix B.

After estimating the thrombus volume

at each of the specified times, a plot of thrombus volume vs. time was constructed.
Of the 45 thrombi analyzed, 32 contained data beginning early in the thrombus growth
process, and only these were used for thrombus growth evaluation (19 in the small tubes and 13
in the large tubes). An evaluation of thrombus volume vs. time showed that thrombus growth in
the small and large tubes followed separate patterns. Of the 19 thrombi in the small tubes that
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were analyzed, 17 showed a growth pattern similar to that of a power-law relationship as a
function of time. Twelve of the 13 thrombi in the large tubes that were analyzed showed a
growth pattern similar to that of linear growth. Examples of the small and the large tube
thrombus growth patterns are shown in Figure 27.

Figure 27: Thrombus volume vs. time A) in a small tube and B) in a large tube.
The difference in thrombus growth patterns between the small and large tubes can be
explained by analyzing the methods of transport of blood components to existing thrombi. As
shown in Figure 14, the location where thrombus growth occurs in the small tubes has a
relatively high flow velocity and is likely dominated by the convection of blood components to
an existing thrombus. (The Sherwood number for a tube without a thrombus is reported to be
3.66 [40]).
As a thrombus grows in the small tube, the flow becomes more constricted and the
velocity increases, which leads to an increase in the convective transport of blood components to
the thrombus. The Sherwood number of an entry region for laminar flow that is not fully
developed can be approximated by the following correlation [40].
Sh

.

1.86
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(36)

For the experimental conditions in the study where the temperature is constant, the viscosity ratio
reduces to 1. As the velocity increases due to a growing thrombus, the Reynolds number in
Equation 36 will increase, which leads to an increase in the Sherwood number. This implies that
the effects of the convective transport of blood components to an existing thrombus have
increased.
In the large tubes, the velocity surrounding the growing thrombus is near-zero (Figure 14),
and therefore, the associated Reynolds number will be close to 0 and the Sherwood number will
be close to 1. This Sherwood number approximation reflects that the transport of blood
components to the thrombus in the large tubes is dominated by diffusion. As the thrombus
volume increases in this location, the flow profile around the growing thrombus is not altered
significantly, and therefore there is no impact on thrombus growth rate.
An increase in the velocity of blood flow due to a growing thrombus in the small tubes
will also increase the shear stress related to blood flow. This raises a question of whether shearrelated platelet activation can occur [41]. The estimated range of shear stress for the
experimental conditions in this study is 100 to 500 dynes/cm2 and the estimated range for the
exposure time is 0.1 to 5 milliseconds. An example of this estimation is shown in Appendix C.
According to the criteria proposed by Hellums, this range of shear stress and exposure time is
well below the threshold for activation of platelets by shear stress [41], and thus, there should not
be an effect on thrombus growth due to platelet activation caused by an increase in shear stress.
The thrombus growth rate in the large and small tubes were compared by plotting
thrombus growth rate with respect to time, as shown in Figure 28. The magnitude of change in
the thrombus growth rate (increase or decrease) was determined by evaluating the slope of
thrombus growth rate over time.
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Figure 28: An example of thrombus growth rate vs. time in A) small tubes and
B) large tubes.
The average slopes of thrombus growth rate with respect to time for thrombi in small tubes (n
=19) and that for large tubes (n=13) are presented in Table 2. The slope of thrombus growth rate
in the small tubes was significantly greater than that of the large tubes. Such a large difference
in the slope of thrombus growth over time between the small and the large tubes is consistent
with the idea of convection domination in the small tubes and the diffusion domination in the
large tubes as discussed earlier.
Table 2: Slope of thrombus growth rate with respect to time
Slope of Thrombus Growth Rate (mL/s2)
5.72E‐07 ± 2.64E‐07 (95% confidence)
1.34E‐07 ± 6.08E‐08 (95% confidence)
0.013

Small Tubes (n = 19)
Large Tubes (n = 13)
p‐value

Effect of Heparin Concentration on Thrombus Growth Rate
As discussed in Section 2.4, one possible effect of an increase in heparin concentration
in the blood is a decrease in thrombus formation by inhibiting the participation of fibrin, thus
decreasing thrombus growth rate. The results in Table 3 showed that no such effect was present;
however, due to the small number of data points, there was no significant difference either way.
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When evaluating paired differences within donors, results varied widely and the differences were
not statistically significant.
Table 3: Effect of heparin concentration on slope of
thrombus growth rate over time
Small Tubes
Heparin Concentration = 0.5 units/mL (n = 6)
Heparin Concentration = 0.75 units/mL (n = 4)
p‐value

Mean ± 95% conf. interval (mL/s2)
6.25E‐07 ± 5.53E‐07
8.25E‐07 ± 8.63E‐07
0.697

Large Tubes
Heparin Concentration = 0.5 units/mL (n = 2)
Heparin Concentration = 0.75 units/mL (n = 2)
p‐value

Mean ± 95% conf. interval (mL/s2)
1.50E‐07 ± 9.80E‐08
2.50E‐07 ± 9.80E‐08
0.293

Effect of Flow Rate on Thrombus Growth Rate
A decrease in blood flow rate can lead to a decrease in the convective transport of
platelets and other blood components to an existing thrombus, which would decrease thrombus
growth rate. However, a decrease in blood flow rate can also lead to an increase in residence
time of blood around the existing thrombus, which would increase thrombus growth rate. The
results from Table 4 suggest a decrease in the slope of thrombus growth rate with decreasing
flow rate in both the small and large tubes. However, the results were not statistically
significant, even when individual donors were evaluated.
Table 4: Effect of flow rate on the slope of thrombus growth rate over time
Small Tubes
Flow Rate = 1.0 mL/min (n = 6)
Flow Rate = 0.5 mL/min (n = 5)
p‐value

Mean ± 95% conf. interval (mL/s2)
6.25E‐07 ± 5.53E‐07
3.24E‐07 ± 2.68E‐07
0.393

Large Tubes
Flow Rate = 1.0 mL/min (n = 2)
Flow Rate = 0.5 mL/min (n = 1)
p‐value

Mean ± 95% conf. interval (mL/s2)
1.50E‐07 ± 9.80E‐08
7.00E‐08
N/A
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Effect of Device Design on Thrombus Growth Rate
An experiment was conducted to demonstrate an application of the developed method to
study the effect of change in device design on the thrombus growth rate. As discussed
previously in Section 5, the spacing between the two small tubes was decreased from 1 mm to
0.5 mm. As this change in device design only affects the flow pattern of the blood at locations
between two successive small tubes, only thrombus data from these locations were analyzed.
From the 45 thrombi analyzed, 8 (2 from the baseline experiment and 6 from the decreasedspacing experiment) qualified for this study.
A decrease in the spacing between two successive small tubes resulted in a flow pattern
where the main flow stream does not re-attach to the surface of the large tube following the
expansion created at the end of a small tube. This created a larger recirculation zone at the
surface. Assuming that the growth mechanism for thrombi in this location is diffusion controlled,
one possible result of this change in device design would be a decrease in the slope of thrombus
growth rate because the diffusion distance from the main flow stream to the existing thrombus
has increased due to no flow reattachment to the surface. The results suggest that a decrease in
the spacing between two successive small tubes leads to a significant decrease in slope of
thrombus growth rate (Table 5).
Table 5: Effect of device design on the slope of thrombus growth rate over time
Mean ± 95% conf. interval (mL/s2)
1.50E‐07 ± 9.80E‐08
6.17E‐08 ± 2.60E‐08
0.039

Large Middle Tubes
Spacing = 1 mm (n = 2)
Spacing = 0.5 mm (n = 6)
p‐value
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7.1.3 Thrombus Growth Direction
Thrombus growth direction was estimated by tracking the thrombus center of mass with
respect to time. The output from Image J for center of mass was given in Cartesian coordinates
with the origin located at the upstream edge of the thrombus adjacent to the biomaterial surface.
The assumption made in this approximation is that the three-dimensional shape of the thrombus
can be sufficiently represented by a two-dimensional image. An example of the center of mass
changing with respect to time, using Cartesian coordinates in two dimensions, is shown in Figure
29.

Figure 29: Change in thrombus center of mass with respect to time.
Of the 45 thrombi analyzed, 29 were used for this study. The remaining 16 were rejected
due to one of two reasons: 1) thrombus growth was not captured during the early stages of
growth and 2) thrombus growth was captured from an angle that was not comparable to other
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videos. After the center of mass data were collected, they were graphed in Cartesian coordinates
to determine the direction of thrombus growth. An example of this is shown in Figure 30.

Figure 30: An example of the thrombus center of mass change, in Cartesian
coordinates.
To quantify the direction of the center of mass change, and thus direction of thrombus
growth, an equation was fit to the data with the trendline function in Excel (Microsoft®). The
best fit to the data was determined to be a straight line and the slope of that line was used to
calculate the thrombus growth direction angle, which typically ranged from 15 to 35 degrees.
Thrombus growth angles for the large and small tubes were not significantly different (Table 6).
Table 6: Thrombus growth direction in the small and large tubes
Thrombus Growth Direction (degrees)
25.78 ± 5.22 (95% confidence)
23.59 ± 12.96 (95% confidence)
0.637

Small Tubes (n = 18)
Large Tubes (n = 11)
p‐value
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Effect of Heparin Concentration on Thrombus Growth Direction
One possible effect of heparin concentration on thrombus growth direction might be that
it affects the mechanical strength of the developing thrombus. An increase in heparin
concentration in blood could lead to a decrease in mechanical strength of thrombi due to a
decrease in fibrin participation during thrombus growth. Thus, it is possible that the developed
thrombus at higher heparin concentration could deform more easily as blood flow tends to push
the thrombus downstream. However, no such effect is suggested by the data (Table 7).
Table 7: Effects of heparin concentration in blood in thrombus growth direction
Small Tubes
Heparin Concentration = 0.5 units/mL (n = 6)
Heparin Concentration = 0.75 units/mL (n = 5)
p‐value

Mean ± 95% conf. interval (degrees)
27.66 ± 9.29
25.48 ± 2.79
0.696

Large Tubes
Heparin Concentration = 0.5 units/mL (n = 3)
Heparin Concentration = 0.75 units/mL (n = 2)
p‐value

Mean ± 95% conf. interval (degrees)
25.27 ± 13.91
22.03 ± 24.79
0.821

Effect of Flow Rate on Thrombus Growth Direction
A decrease in flow rate can lead to an increase in thrombus growth direction because less
force is pushing the thrombus downstream. However, the results show no significant difference
in thrombus growth direction in either the small or large tubes (Table 8).
Table 8: Effect of flow rate on the thrombus growth direction
Small Tubes
Flow Rate = 1.0 mL/min (n = 6)
Flow Rate = 0.5 mL/min (n = 3)
p‐value

Mean ± 95% conf. interval (degrees)
27.66 ± 9.29
32.47 ± 21.45
0.644

Large Tubes

Mean ± 95% conf. interval (degrees)

Flow Rate = 1.0 mL/min (n = 3)
Flow Rate = 0.5 mL/min (n = 1)
p‐value

25.27 ± 13.91
23.12 ± 14.16
N/A
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Effect of Device Design on Thrombus Growth Direction
As described in Section 7.1.2, only results from the thrombi that grew in the large tube
between two successive small tubes were considered. As the velocity at the location where the
thrombus grows in the large tubes is near zero for both cases, this device design change should
lead to no effect on thrombus growth direction, consistent with results presented in Table 9.
Table 9: Effect of device design on thrombus growth direction
Large Middle Tubes
Spacing = 1 mm (n = 3)
Spacing = 0.5 mm (n = 5)
p‐value

Mean ± 95% conf. int. (degrees)
25.27 ± 13.91
23.12 ± 14.16
0.851

7.1.4 Shear Force Acting on the Thrombus
Shear force on observed thrombi was estimated according to the calculations shown in
Chapter 6. As discussed in Section 7.2, a thrombus boundary equation was obtained from Image
J at specified times. This thrombus boundary equation was then used as an input for calculating
shear force on the thrombus. A sample of the shear force calculation is shown in Appendix C.
A plot of the calculated shear force on a thrombus with respect to time is shown in Figure 31.

Figure 31: An example of shear force acting on a thrombus with respect to time for
A) small tubes B) large tubes.
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For each thrombus growth observed, the shear force acting on it was calculated at specified time
intervals (in most cases 30 seconds) to analyze how the shear force changed as the thrombus
grew.
The pattern of shear force acting on the thrombus with respect to time mirrored the
pattern of thrombus volume change. For thrombi in the small tubes, the shear force acting on the
thrombus increased as a power-law-like function of time. For thrombi in the large tubes, the
shear force acting on the thrombus increased as a linear-like function of time. As the factors that
determine the shear force acting on the thrombus (mainly the blood flow velocity and the surface
area of the thrombus) depend on the size of the thrombus, it seems logical that the pattern of
shear force acting on the thrombus with respect to time would follow that of thrombus volume
growth.
7.2 Embolization
The mechanism of embolization is difficult to determine due to the limited temporal and
spatial resolution of the current experimental techniques. Embolization occurred so quickly that
it was difficult to capture the detail necessary to determine the mechanism. However, after
observing the several high-definition videos acquired, the following two mechanisms can be
proposed:
1) Complete detachment of a thrombus from the foreign surface
2) Partial embolization of a thrombus by internal tearing
The first mechanism is shown in Figure 32 where the entire thrombus stays intact and seems to
slide down the surface before embolizing.
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Figure 32: Thrombus sliding along the surface of the biomaterial surface before
embolizing.
Alternatively, partial embolization can sometimes occur by internal tearing of the thrombus due
to the shear forces acting on the thrombus. Although the partial embolization of a thrombus was
very difficult to observe in detail, a few of the videos acquired showed a change in shape of
thrombus which proved that the partial embolization can occur.
7.2.1 Calculation of Shear Force Acting on the Thrombus at Embolization
From the 45 thrombi analyzed, 19 thrombi that grew in the small tubes and 4 thrombi that
grew in the large tubes embolized. Of the 19 thrombi that embolized in the small tubes, 3 were
rejected because visual observation showed that they either embolized due to impact from an
embolus released at an upstream location or because an attachment (another thrombus) to the
thrombus was visible at embolization but not during thrombus growth.
Comparing the 16 embolization events from the small tubes and 4 from the large tubes
showed that the shear force at which the thrombus embolized was significantly higher for
thrombi in the small tubes (Table 10).
Table 10: Shear force acting on the thrombus at embolization
Shear Force at Embolization (N)
1.79E‐06 ± 5.05E‐07 (95% confidence)
3.49E‐07 ± 3.42E‐07 (95% confidence)
0.014

Small Tubes (n = 16)
Large Tubes (n = 4)
p‐value
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The higher shear force acting on the thrombus at embolization for thrombi in the small tubes can
be explained in two possible ways. First, thrombi in the large tubes were embolizing due to
factors other than just the shear force acting on the thrombus, such as being impacted by emboli
released at an upstream location. All 4 videos of large-tube embolization had thrombi that were
large enough to protrude into the upstream emboli path, and one of the 4 videos available
actually showed an embolization event associated with a collision from an upstream embolus.
Another possible explanation is that the thrombi that grow in the small tubes may be a
different type of thrombus than those that grow in the large tubes, and therefore they embolize at
a different shear force threshold. The high-flow velocity in the small tubes might prevent red
cells from being captured by the thrombus, which would result in the development of what is
often referred to as a white thrombus. In the large tubes, low-flow velocity results in many red
cells becoming part of the thrombus and forming what is often referred to as a red thrombus [42].
However, due to the presence of heparin, which inhibits fibrin formation, thrombi that grow in
the large tubes are not the typical red thrombus that includes fibrin; rather they are more like
white platelet thrombi that also captured some red blood cells. This was consistent with
experimental observations wherein thrombi that formed in the small tubes appeared more solidly
white than thrombi that grew in the large tubes, which were more red in color (see Figure 23).
In an analysis of the effect of controlled variables on the shear force at embolization, only
4 of the 21 analyzed thrombi in the large tubes embolized, thus not enough data were collected to
report any results for embolization in the large tubes. For thrombi in the small tubes, both an
increase in heparin concentration and a decrease in flow rate resulted in shear forces at the time
of embolization that were not statistically different from the baseline experiments (Table 11).
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Table 11: Effect of heparin concentration and flow rate
on the shear force at embolization
Hep. Conc. = 0.5 units/mL, Flow Rate = 1 mL/min (n=8)
Hep. Conc. = 0.75 units/mL, Flow Rate = 1 mL/min (n=3)
Hep. Conc. = 0.5 units/mL, Flow Rate = 0.5 mL/min (n=2)

Mean ± 95% conf. int. (N)
1.89E‐06 ± 8.59E‐07
2.04E‐06 ± 1.48E‐06
1.93E‐06 ± 2.86E‐07

p‐value
0.861
0.966

7.2.2 Adhesion Strength
The hypothesis describing embolization is that it occurs when the shear force on a
thrombus exceeds the adhesion strength between the thrombus and the foreign surface.
Associated with this hypothesis is the expectation that the estimated shear force per estimated
thrombus-biomaterial attachment area (Fshear/Aattached) would start out less than some critical
value during early development of the thrombus and would increase to that critical value as the
thrombus grows, at which time, embolization would occur. In fact, the evaluation of
Fshear/Aattached in a few representative thrombi demonstrated that pattern (Figure 32).

Figure 33: Shear force acting on a thrombus divided
by assumed thrombus attachment area.
Figure 33 shows that for one of the thrombi examined, Fshear/Aattached initially decreased
but as the thrombus grew, this ratio began to increase until the threshold limit for embolization
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was exceeded. The decrease of Fshear/Aattached in the initial phase was unexpected, and could be a
real phenomenon or be occurring as a result of the assumptions made about the thrombus shape
(Chapter 6).
The adhesion strength of a thrombus to a foreign surface was estimated using the
estimated shear force at the time of embolization and dividing it by the estimated thrombusbiomaterial attachment area. An example of this calculation is shown in Appendix D. As with
the calculation of shear force at the time of embolization, only 16 thrombi from the small tubes
were analyzed. The results of adhesion strength of thrombi are presented in Table 12.
Table 12: Thrombus adhesion strength in the small and large tubes
Adhesion Strength (N/m2)
16.24 ± 2.59 (95% confidence)

Small Tubes (n=16)

The adhesion strength for thrombi in the small tubes ranged from 9.63 to 28.83 N/m2 with an
mean value of 16.24 ± 2.59 N/m2 (95% confidence). This result is remarkably close to the results
published by Goodman [43] for the removal of platelets by various values of shear stress using
radiolabeling and scanning electron microscopy. From Goodman’s data, 70 - 90% removal of
platelets occurred at shear stresses of 13 - 25 N/m2.
The effects of changes in heparin concentration and flow rate on the adhesion strength of
thrombi in the small tubes were analyzed (Table 13). The results suggest that neither a change in
heparin concentration nor flow rate had a statistically significant effect on thrombus adhesion
strength.
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Table 13: Effect of heparin concentration and flow rate on the adhesion strength
Hep. Conc. = 0.5 units/mL, Flow Rate = 1 mL/min (n=8)
Hep. Conc. = 0.75 units/mL, Flow Rate = 1 mL/min (n=3)
Hep. Conc. = 0.5 units/mL, Flow Rate = 0.5 mL/min (n=2)

Ave. ± 95% conf. int. (N/m2) p‐value
17.40 ± 4.36
18.18 ± 4.23
0.846
14.96 ± 4.12
0.619

7.2.3 Light-Scattering Microemboli Detector Output Analysis
The light-scattering microemboli detector (LSMD) detected the number and size of
emboli passing through the flow cell by differentiating the light-scattering patterns created by
emboli from patterns created by the red blood cells and other blood components [37]. The
LSMD reports four separate streams of data with respect to time. These outputs include:
1) Instantaneous peak: detection of a single embolus or single group of emboli
2) Cumulative peak: sum of all emboli that have passed the detector from time = 0
3) Instantaneous moment: length scale (diameter) of the detected embolus or group of
emboli
4) Cumulative moment: sum of instantaneous moments from time = 0
Although the cumulative peak count of thrombi data is important, the most informative of these
outputs is the cumulative moment because it represents the sum of emboli diameters that were
detected throughout the entire experiment.
In the study of the effects of “controlled variables” (heparin concentration, flow rate, and
device design), the cumulative peak count and cumulative moment were also recorded by the
LSMD. Since the LSMD detects many more emboli than could be tracked by videomicroscopy,
sufficient data were available to use a paired-difference analysis. Because the response of blood
to the experimental conditions varies from donor to donor and even from day to day for the same
donor, this kind of paired-difference analysis minimizes the effects of donor and day-to-day
variations and focuses more directly on the variable of interest. Thus for each donor on each day,
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the difference was computed between the cumulative peak count for the conditions of altered
controlled variable (e.g. increased heparin concentration, etc.) versus for the baseline conditions.
A similar difference was computed for the cumulative moment. The means of those paired
differences were evaluated against the null value of zero using the Student t-test (see Table 14).
Table 14: The means of cumulative peak count and cumulative moment
Mean of Cumulative Peak
Count % Change
± 95% Confidence Interval

Increase in Heparin Concentration
(from 0.5 units/mL to 0.75 units/mL)
(n = 7)
Decrease in Flow Rate
(from 1 mL/min to 0.5 mL/min)
(n = 3)
Decrease in Spacing between Tubes
(from 1 mm to 0.5 mm)
(n = 5)

p‐values

Mean of Cumulative
Moment % Change
± 95% Confidence Interval

p‐values

‐37.82% ± 25.59%

0.013

‐42.47% ± 19.53%

0.001

‐24.93% ± 59.53%

0.458

‐71.32% ± 36.90%

0.019

17.79% ± 58.55%

0.568

21.50% ± 38.74%

0.308

An increase in heparin concentration of blood led to a 38% decrease in the cumulative
peak count and a 42% decrease in the cumulative moment. These results are in agreement with
the notion that an increase in the heparin concentration in the blood decreases the fibrin
participation in thrombus formation and thus decreases the formation of emboli large enough to
be seen by the LSMD. A decrease in flow rate resulted in a significant decrease in the
cumulative moment; however the cumulative peak count difference was insignificant. Also, a
decrease in the spacing between the two small tubes (inserts) resulted in no significant difference
both cumulative peak count and cumulative moment.
7.3 Comparison of Experimental Results to Andersen CFD Model
Andersen developed a real-time three-dimensional CFD model for predicting thrombus
formation and embolization in blood-contacting devices [44]. As part of the current research,
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experimental results were compared to this CFD model results under the same conditions as
those used in our experiments.
The thrombus growth locations predicted by the Andersen CFD model for the same
conditions used in this research are shown in Figures 34 and 35. Figure 34 is a prediction of
thrombus formation in the flow cell at t = 1044. Figure 35 represents the fraction of time
occupied by thrombi throughout an entire 1200-second simulation. Color variations represent
the fractions of time that each location was a thrombus.
A)

B)

C)

D)

Figure 34: Thromboembolism predictions from Andersen CFD model at t = 1044 seconds
A) experiment 1 B) experiment 2 C) experiment 3 and D) experiment 4 [see Table 1].
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A)A)

B)

C)

D)

Figure 35: Fraction of time occupied by a thrombus for 1200 second simulations
A) experiment 1 B) experiment 2 C) experiment 3 and D) experiment 4 [see Table 1].
For the most part, the CFD model predictions for thrombus growth locations disagreed
with observations from current experimental study. The CFD model predicts that most of the
thrombus growth exists upstream of the small-tube inserts near the entrance region of the flow
cell. Experimental observations from the current research show that most thrombus growth
occurs just upstream or just downstream of the small tubes. Also according to experimental
observation, thrombi often grow at the leading edge of the small tubes, which is not reflected in
the CFD model predictions.

63

The mean cumulative emboli counts of 8 donors for each of the experimental conditions
at t = 1200 seconds are presented and compared to CFD predicted emboli counts at t = 1200
seconds (Table 15).
Table 15: Mean paired differences for cumulative peak count and cumulative
moment (altered conditions minus baseline conditions). P-values reflect
the probability of the differences equaling zero.
Experiment Emboli
Count at t=1200s ± 95%
Conf. Interval
Baseline Experiment (n = 7)
Increase in Heparin Concentration
(from 0.5 to 0.75 units/ml) (n = 7)
Decrease in Flow Rate
(from 1 mL/min to 0.5 mL/min) (n = 4)
Decrease in Spacing between Small Tubes
(from 1 mm to 0.5 mm) (n = 6)

p‐value

CFD Predicted Emboli
Count at t = 1200s

244.14 ± 169.87

22210

164.43 ± 91.44

0.434

21860

160.00 ± 122.87

0.574

20352

203.10 ± 111.30

0.731

16081

The CFD-predicted emboli count was about two orders of magnitude higher than the
mean experimental count. However, the vast majority of emboli predicted by the CFD model are
in the 20-30 micron range, which is much smaller than the detection limit of the LSMD.
Therefore, a direct comparison between experimental emboli count and the CFD model
prediction cannot be made.
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CHAPTER 8: SUMMARY AND CONCLUSIONS

In this work, a unique and novel method to study thromboembolism by direct observation
was developed. High-definition videos of thrombus formation and embolization in miniature
flow cells that mimic blood-contacting devices using in-vitro, non-invasive, real-time techniques
were successfully obtained.

The obtained videos were analyzed using the image-analysis

software, Image J (National Institutes of Health) to determine critical parameters of
thromboembolism such as thrombus growth rate, thrombus growth direction, shear force acting
on the thrombus with respect to time, shear force on the thrombus at embolization, and adhesion
strength of the thrombus to the foreign surface. Also, characteristics of thrombus growth
location and embolization were observed and reported.
For the flow cell used, the thrombus growth was found in predominantly two locations.
Thrombi grew in the flow recirculation zone just after the trailing edge of the small tubes 53% of
the time. For the remaining 47% of the time, thrombi grew at the leading edge of the small tubes.
However, several thrombus growth video observations suggest that at least some, if not all,
thrombus formation in the small tubes actually starts in the flow recirculation zone just before
the leading edge of the small tubes and then spreads into the small tubes. It can be concluded
from these results that flow recirculation zones play a major role in initial thrombus formation.
After estimating the thrombus volume and shear force acting on the thrombus at specified
times, patterns of thrombus growth for small and large tubes were identified. In the small tubes,
thrombus volume and shear force acting on the thrombus showed a growth pattern that behaved
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like a power-law function of time. In the large tubes, thrombus volume and shear force
acting on the thrombus showed a growth pattern that was like a linear function of time. The
difference in patterns of thrombus growth and shear force acting on the thrombus between the
small and large tubes was explained by the methods of transport of blood components. The
location where thrombus growth occurred in the small tubes had a high flow velocity and is
likely to be dominated by the convection of blood components to an existing thrombus; however,
the recirculation zone in the large tubes that promotes thrombus growth has near-zero velocity,
and thus the transport of blood components to an existing thrombus is dominated by diffusion.
The average slopes of thrombus growth rate with respect to time for thrombi in small
tubes and that for large tubes were determined. The slope of thrombus growth rate in the small
tubes was significantly greater than that in the large tubes. The thrombus growth direction was
determined by tracking the thrombus center of mass with respect to time. To quantify the
direction of the center of mass change, and thus direction of thrombus growth, a straight line was
fit to the data and the slope of that line was used to calculate the thrombus growth direction angle,
which typically ranged from 15 to 35 degrees from the direction of flow. The difference
between thrombus growth angles for the large and small tubes was insignificant.
According to a frame-by-frame observation of embolization videos, embolization seems
to occur via two possible mechanisms: complete detachment of the thrombus by sliding off the
foreign surface or partial embolization of the thrombus by internal tearing. The difference of
shear force on the thrombus at the time of embolization between the small and the large tubes
were significant. The shear force at embolization in the small tubes was 1.79E-06 ± 5.05E-07
(95% confidence) and that in the large tubes was 3.49E-07 ± 3.42E-07 (95% confidence). The
difference in shear force at the time of embolization in the small and the large tubes was
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explained by two possible ways. First, thrombi in the large tubes were embolizing due to factors
other than just the shear force acting on the thrombus, such as a result of being impacted by
emboli from upstream. Second, the thrombi that grow in the small tubes could be a different
type of thrombus than those that grow in the large tubes, and therefore they embolize at a
different shear force threshold.
The adhesion strength of a thrombus was calculated for the small tubes using the shear
force at embolization and the estimated thrombus attachment area. The calculated adhesion
strength ranged from 9.63 N/m2 to 28.83 N/m2 with a mean of 16.24 ± 2.59 (95% confidence).
This result is remarkably close to the results published by Goodman [43] for the removal of
platelets by various values of shear stress using radiolabeling and scanning electron microscopy.
From Goodman’s data, 70 - 90% removal of platelets occurred at shear stresses of 13 - 25 N/m2.
Next, the developed method was used to demonstrate that the effects of controlled
variables such as heparin concentration in blood, blood flow rate, and the device design on
thromboembolism could be studied. The changes in controlled variables were:


Heparin concentration in blood - 0.5 units/mL vs. 0.75 units/mL



Blood flow rate - 0.5 mL/min vs. 1.0 mL/min



Spacing between two successive small tubes within the flow cell - 0.5 mm vs. 1.0 mm

The controlled variables were tested one at a time against the baseline experiment results of
critical thromboembolism parameters. Also, paired differences within donors of cumulative peak
count of thrombi and the cumulative moment of thrombi from LSMD output was compared.
Due to the small sample size used in this research, the results from the changes in
controlled variables were statistically insignificant. However, the results suggest that with larger
number of experiments and full factorial experimental design that include variable-variable
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interactions, the developed method can be used to study the effects of controlled variables on
thromboembolism.
Lastly, the observation and data collected from the experiments in this research were
compared to the predictions of a CFD model developed by Andersen [44] under identical
conditions. For the most part, the CFD model predictions for the thrombus growth locations
disagreed with experimental observations. The emboli count comparison couldn’t be directly
made because the vast majority of emboli predicted by the CFD model are in the 20-30 micron
range, which is much smaller than the detection limit of LSMD. However, both models did
show the importance of flow recirculation zones for thromboembolism activity and similar trends
for changes in three controlled variables.
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CHAPTER 9: FUTURE DIRECTION

While current experimental techniques for capturing the details of thromboembolism
under a microscope performed sufficiently well for this work, significant improvements can be
made in the experimental setup and methods employed to obtain results that would be both more
consistent and more accurate.
The most significant improvements that can be made to the experimental setup would be
to acquire a higher-quality microscope and high-definition camera. A microscope with better
optics and a high-definition camera with a higher recording frame rate would allow for a better
visual image of thrombus growth, but more importantly, would be able to capture embolization
events in higher detail. Also, with an improved video recording system, rather than focusing
only on one part of the flow cell, the entire flow cell could be observed with the same or better
quality image of thrombus growth and embolization.
Although it may be very difficult to achieve, developing a three-dimensional camera
system that could observe thrombus growth from all angles surrounding the flow cell would
significantly improve the quality of results. The largest assumption made by the current research
was to approximate the three-dimensional thrombus shape with an acquired two-dimensional
image.
Video recordings of thrombus growth for initial experiments conducted in the current
research began once thrombus formation was observed. This frequently resulted in a lack of data
during the initial stages of thrombus growth. A better method of recording would have been to
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start the recording process immediately after blood entered the flow cell. Also, using a
parallel means of analysis for testing the effects of all controlled variables on thromboembolism
would be ideal because blood from a single donor can respond differently on a day-to-day basis.
Lastly, increasing the pool of donors and number of experiments while using a full
factorial design of controlled variables would help to increase the confidence in the experimental
results.
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APPENDIX A – AN EXAMPLE OF IMAGE J BOUNDARY DATA OUTPUT

X_raw

Y_raw

Y_zeroed

Y_adjusted

X (mm)

Y (mm)

Y MIN:

116.059

1.000

120.447

4.388

7.638

0.001

0.010

Y_ZEROED MAX:

48.259

2.000

123.624

7.565

13.167

0.003

0.017

HEIGHT:

84.000

3.000

125.129

9.071

15.788

0.004

0.020

PIXELS (pixels/mm):

4.000

126.471

10.412

18.123

0.005

0.023

RATIO:

5.000

127.894

11.835

20.601

0.006

0.026

6.000

129.365

13.306

23.160

0.008

0.029

7.000

131.341

15.282

26.601

0.009

0.034

8.000

133.259

17.200

29.939

0.010

0.038

9.000

135.047

18.988

33.051

0.011

0.042

10.000

136.471

20.412

35.529

0.013

0.045

11.000

137.741

21.682

37.741

0.014

0.048

12.000

139.247

23.188

40.362

0.015

0.051

13.000

140.353

24.294

42.287

0.017

0.054

14.000

141.741

25.682

44.703

0.018

0.057

15.000

142.635

26.576

46.259

0.019

0.059

16.000

143.812

27.753

48.307

0.020

0.061

17.000

144.976

28.918

50.334

0.022

0.064

18.000

145.906

29.847

51.952

0.023

0.066

19.000

147.012

30.953

53.877

0.024

0.068

20.000

147.988

31.929

55.577

0.025

0.071

21.000

148.576

32.518

56.601

0.027
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22.000

149.329

33.271

57.911

0.028
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23.000

150.000

33.941

59.079

0.029
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24.000

150.776

34.718
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0.031

0.077

25.000

151.694

35.635

62.027
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0.079
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152.318

36.259

63.113

0.033
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27.000

153.082

37.024

64.444

0.034
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28.000

153.659
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65.447
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154.612

38.553

67.106

0.037
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155.388

39.329

68.457
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156.153

40.094

69.788
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156.553

40.494

70.485

0.041
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33.000
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40.988

71.345
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0.091

75

786.670
1.741
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157.624

41.565

72.348

0.043
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158.341

42.282
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45.094

78.491

0.053

0.100

43.000

161.247
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45.506

79.208
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162.282
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46.435

80.826
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162.518

46.459

80.867
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47.212
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163.012
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81.727

0.065

0.104
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47.118
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83.324
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45.318
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160.729

44.671
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160.118

44.059

76.689

0.094

0.097
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43.471
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0.096
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158.694

42.635

74.212
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157.529

41.471

72.184
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0.092
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156.435

40.376

70.280
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0.089
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155.565

39.506

68.765

0.100

0.087

80.000

153.988

37.929

66.020

0.102

0.084

81.000

152.847

36.788

64.034

0.103

0.081

82.000

151.965

35.906

62.498

0.104

0.079

83.000

150.953

34.894

60.737

0.106

0.077

84.000

150.012

33.953

59.099

0.107

0.075

85.000

149.765

33.706

58.669

0.108

0.075

86.000

149.059

33.000

57.440

0.109

0.073

87.000

148.118

32.059

55.802

0.111

0.071

88.000

147.341

31.282

54.451

0.112

0.069

89.000

146.682

30.624

53.304

0.113

0.068

90.000

146.165

30.106

52.403

0.114

0.067

91.000

145.576

29.518

51.379

0.116

0.065

92.000

144.906

28.847

50.212

0.117

0.064

93.000

144.012

27.953

48.655

0.118

0.062

94.000

142.988

26.929

46.874

0.119

0.060

95.000

142.141

26.082

45.399

0.121

0.058

96.000

141.635

25.576

44.519

0.122

0.057

97.000

140.824

24.765

43.106

0.123

0.055

98.000

139.812

23.753

41.345

0.125

0.053

99.000

139.071

23.012

40.055

0.126

0.051

100.000

138.118

22.059

38.396

0.127

0.049

101.000

137.706

21.647

37.679

0.128

0.048

102.000

137.000

20.941

36.451

0.130

0.046

103.000

136.306

20.247

35.242

0.131

0.045

104.000

135.365

19.306

33.604

0.132

0.043

105.000

134.718

18.659

32.478

0.133

0.041

106.000

134.118

18.059

31.433

0.135

0.040

107.000

133.435

17.376

30.246

0.136

0.038

108.000

132.824

16.765

29.181

0.137

0.037

109.000

131.588

15.529

27.031

0.139

0.034

110.000

131.153

15.094

26.273

0.140

0.033

111.000

129.953

13.894

24.184

0.141

0.031

112.000

129.212

13.153

22.894

0.142

0.029

113.000

128.165

12.106

21.072

0.144

0.027

114.000

127.412

11.353

19.761

0.145

0.025

115.000

126.776

10.718

18.655

0.146

0.024
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116.000

126.071

10.012

17.427

0.147

0.022

117.000

125.471

9.412

16.382

0.149

0.021

118.000

124.729

8.671

15.092

0.150

0.019

119.000

123.753

7.694

13.393

0.151

0.017

120.000

122.824

6.765

11.775

0.153

0.015

121.000

122.024

5.965

10.382

0.154

0.013

122.000

121.541

5.482

9.543

0.155

0.012

123.000

120.918

4.859

8.457

0.156

0.011

124.000

120.259

4.200

7.311

0.158

0.009

125.000

119.659

3.600

6.266

0.159

0.008

126.000

118.894

2.835

4.935

0.160

0.006

127.000

118.388

2.329

4.055

0.161

0.005

128.000

118.071

2.012

3.502

0.163

0.004

129.000

117.529

1.471

2.560

0.164

0.003

130.000

117.200

1.141

1.986

0.165

0.003

131.000

117.035

0.976

1.700

0.167

0.002

132.000

116.612

0.553

0.962

0.168

0.001

133.000

116.741

0.682

1.188

0.169

0.002

134.000

116.059

0.000

0.000

0.170

0.000
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APPENDIX B – AN EXAMPLE OF THROMBUS VOLUME CALCULATION
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APPENDIX C – AN EXAMPLE OF SHEAR STRESS AND EXPOSURE TIME FOR
HELLUMS’S CURVE TEST
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APPENDIX D – AN EXAMPLE OF SHEAR FORCE ACTING ON A THROMBUS
CALCULATION
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APPENDIX E – AN EXAMPLE OF THROMBUS ADHESION STRENGTH
CALCULATION
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